JP2021521149A5 - - Google Patents

Info

Publication number
JP2021521149A5
JP2021521149A5 JP2020555339A JP2020555339A JP2021521149A5 JP 2021521149 A5 JP2021521149 A5 JP 2021521149A5 JP 2020555339 A JP2020555339 A JP 2020555339A JP 2020555339 A JP2020555339 A JP 2020555339A JP 2021521149 A5 JP2021521149 A5 JP 2021521149A5
Authority
JP
Japan
Prior art keywords
universal
seq
vaccine composition
composition according
liposome
Prior art date
Application number
JP2020555339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521149A (ja
JPWO2019197414A5 (https=
JP7713213B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/058980 external-priority patent/WO2019197414A1/en
Publication of JP2021521149A publication Critical patent/JP2021521149A/ja
Publication of JP2021521149A5 publication Critical patent/JP2021521149A5/ja
Publication of JPWO2019197414A5 publication Critical patent/JPWO2019197414A5/ja
Priority to JP2025015003A priority Critical patent/JP2025084745A/ja
Application granted granted Critical
Publication of JP7713213B2 publication Critical patent/JP7713213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020555339A 2018-04-10 2019-04-09 抗-aベータ治療用ワクチン Active JP7713213B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015003A JP2025084745A (ja) 2018-04-10 2025-01-31 抗-aベータ治療用ワクチン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18166659 2018-04-10
EP18166659.5 2018-04-10
EP18202366.3 2018-10-24
EP18202366 2018-10-24
PCT/EP2019/058980 WO2019197414A1 (en) 2018-04-10 2019-04-09 Anti-abeta therapeutic vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015003A Division JP2025084745A (ja) 2018-04-10 2025-01-31 抗-aベータ治療用ワクチン

Publications (4)

Publication Number Publication Date
JP2021521149A JP2021521149A (ja) 2021-08-26
JP2021521149A5 true JP2021521149A5 (https=) 2022-04-15
JPWO2019197414A5 JPWO2019197414A5 (https=) 2022-04-15
JP7713213B2 JP7713213B2 (ja) 2025-07-25

Family

ID=66092353

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555339A Active JP7713213B2 (ja) 2018-04-10 2019-04-09 抗-aベータ治療用ワクチン
JP2025015003A Pending JP2025084745A (ja) 2018-04-10 2025-01-31 抗-aベータ治療用ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015003A Pending JP2025084745A (ja) 2018-04-10 2025-01-31 抗-aベータ治療用ワクチン

Country Status (19)

Country Link
US (3) US10828351B2 (https=)
EP (1) EP3773712A1 (https=)
JP (2) JP7713213B2 (https=)
KR (2) KR20250153304A (https=)
AU (1) AU2019253193B2 (https=)
BR (1) BR112020020660A2 (https=)
CA (1) CA3095983A1 (https=)
CL (1) CL2020002586A1 (https=)
CO (1) CO2020013977A2 (https=)
CR (1) CR20200533A (https=)
IL (1) IL277851B2 (https=)
MA (1) MA52180A (https=)
MX (1) MX2020010621A (https=)
MY (1) MY206040A (https=)
PE (1) PE20201344A1 (https=)
PH (1) PH12020551670A1 (https=)
SG (1) SG11202009917PA (https=)
TW (1) TWI908707B (https=)
WO (1) WO2019197414A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773712A1 (en) * 2018-04-10 2021-02-17 AC Immune SA Anti-abeta therapeutic vaccines
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
US20250152684A1 (en) * 2022-02-09 2025-05-15 Ac Immune Sa Anti-Alpha-Synuclein Therapeutic Vaccines
JP2026503655A (ja) * 2023-01-26 2026-01-29 エイシー イミューン ソシエテ アノニム 抗Aβワクチン療法
JP2026505011A (ja) 2023-01-26 2026-02-10 エイシー イミューン ソシエテ アノニム リポソーム構築物
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2248283T3 (es) 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
WO2002066056A2 (en) 2001-02-19 2002-08-29 Pharmexa A/S Synthetic vaccines comprising polyhydroxypolymer carriers
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
WO2004006861A2 (en) 2002-07-17 2004-01-22 Mindset Biopharmaceuticals Usa Inc. Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease
US20060276400A1 (en) 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
EP1992639A4 (en) 2006-02-22 2009-08-26 Hayashibara Biochem Lab PEPTIDE VACCINE FOR INDUCING THE PRODUCTION OF AN ANTIAMYLOID PEPTIDANT BODY
RU2488883C2 (ru) * 2006-03-01 2013-07-27 ТЭГ, ЭлЭлСи Способ для конкурсного выбора отпускаемых по рецепту лекарств и/или поставщика услуг предложения цены
WO2009029272A2 (en) 2007-08-27 2009-03-05 Agadjanyan Michael G Epitope vaccine for prevention and reversion of ad pathology
WO2009090650A2 (en) * 2008-01-16 2009-07-23 Ben-Gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
CN107617110A (zh) 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
ES2616258T3 (es) 2010-03-15 2017-06-12 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna
EP3527220A1 (en) 2010-08-12 2019-08-21 AC Immune S.A. Vaccine engineering
AR083561A1 (es) * 2010-10-26 2013-03-06 Ac Immune Sa Preparacion de una construccion antigenica
JP6240077B2 (ja) * 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
MA40824A (fr) 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
CN105418767B (zh) 2015-12-22 2019-03-08 云南大学 一种用于制备Aβ表位疫苗的融合蛋白及其制备方法和用途
EP3773712A1 (en) * 2018-04-10 2021-02-17 AC Immune SA Anti-abeta therapeutic vaccines

Similar Documents

Publication Publication Date Title
JP2021521149A5 (https=)
JP2025084745A5 (https=)
US7192595B2 (en) Peptide-based vaccine for influenza
JP2012501959A5 (https=)
JP2013181034A5 (https=)
JP5775451B2 (ja) インフルエンザを処置するための組成物および方法
JP2009544614A5 (https=)
JP2021505648A5 (https=)
De Haan et al. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice
AU2019253193B2 (en) Anti-abeta therapeutic vaccines
JP2023052092A (ja) 免疫原性組成物
JP2020534874A (ja) Cd4ヘルパーt細胞エピトープの融合ペプチドおよびそのワクチン
JP2017508006A5 (https=)
KR20200047629A (ko) 인플루엔자 ha 스플릿 백신의 제조 방법
JPWO2019197414A5 (https=)
US10286062B2 (en) Universal influenza vaccine
CL2021003051A1 (es) Terapia de vacuna anti-abeta.
JP2021524280A (ja) ハウスダストダニアレルギーの処置および予防
JP2015525794A5 (https=)
CN102365095B (zh) 分裂gp41
CN101980721B (zh) 含有合成肽的抗原药物赋形剂和使用其的粘膜疫苗
CN106535929A (zh) 增强铝盐吸附疫苗的免疫刺激效力的方法
KR20210135261A (ko) 인플루엔자 ha 스플릿 백신의 제조 방법
CN104507966B (zh) 基于补体组分c5a的疫苗
US11185583B2 (en) Multi-functional mucosal vaccine platform